🇺🇸 FDA
Patent

US 12421249

Inhibitors of APOL1 and methods of using same

granted A61PA61P13/12

Quick answer

US patent 12421249 (Inhibitors of APOL1 and methods of using same) held by Vertex Pharmaceuticals Incorporated expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61P, A61P13/12